NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

心臟衰竭 (HF):全球治療藥市場預測與分析 (到2028年)

Heart Failure: Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品編碼 296455
出版日期 內容資訊 英文 190 Pages
訂單完成後即時交付
價格
心臟衰竭 (HF):全球治療藥市場預測與分析 (到2028年) Heart Failure: Global Drug Forecast and Market Analysis to 2028
出版日期: 2019年12月31日內容資訊: 英文 190 Pages
簡介

本報告提供全球心臟衰竭 (HF) 治療藥的市場相關分析,疾病概要和流行病學的背景,患病人數趨勢預測,臨床實驗的進展,已上市/臨床實驗中主要的調查治療藥,目前市場未滿足需求,主要企業的簡介,全球/主要國家的市場趨勢預測等。

第1章 目錄

第2章 心臟衰竭:摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理生理學
  • 分類、病期分類系統
  • 症狀
  • 預後

第5章 流行病學

  • 疾病的背景情況
  • 風險要素與並存症
  • 世界各國的變化
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
  • 心臟衰竭 (HF)的流行病學的預測 (2018∼2028年)
    • 心臟衰竭的已受診患病人數
    • 心臟衰竭的已受診患病人數:各年齡
    • 心臟衰竭的已受診患病人數:男女
    • 心臟衰竭的已受診患病人數:各射血分數 (EF)
    • 急性心臟衰竭 (AHF)的住院患者數
    • 急性心臟衰竭 (AHF) 患者的住院期間
    • 急性心臟衰竭 (AHF) 患者的再住院率 (30日以內)
    • 慢性心臟衰竭 (CHF)的已受診患病人數
    • 慢性心臟衰竭 (CHF)的已受診患病人數:各射血分數 (EF)
    • 慢性心臟衰竭 (CHF)的已受診患病人數:各年齡
    • 慢性心臟衰竭 (CHF)的已受診患病人數:男女
    • 慢性心臟衰竭 (CHF)的已受診患病人數:NYHA各分類
    • 擴充性 (PEF)、慢性心臟衰竭 (CHF)的已受診患病人數:各NYHA分類
    • 收縮性 (REF)、慢性心臟衰竭 (CHF)的已受診患病人數:各NYHA分類
    • 慢性心臟衰竭 (CHF)的已受診患病人數:ACCF/AHA分類
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第6章 疾病管理

  • 診斷概要
  • 治療方法概要
    • 治療的指南代表性處方藥
    • 臨床診療
  • 美國
  • (5EU)歐洲主要5個國家
  • 日本
  • 中國

第7章 競爭評估

  • 概要

第8章 未滿足需求及市場機會分析

  • 概要
  • 擴張性心臟衰竭 (HF-PEF) 患者治療藥的不足
  • 收縮性心臟衰竭 (HF-REF) 患者治療藥的不足
  • 有腎臟功能障礙的患者治療藥的不足
  • 有心臟衰竭發病風險的患者的預防藥
  • 心臟衰竭治療藥的服藥遵守和最適量服藥
    • 未滿足需求

第9章 開發平台評估

  • 概要
  • 臨床實驗中有前途的醫藥品
  • 開發平台醫藥品的障礙

第10章 現在、未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • Amgen and Cytokinetics
    • 概要
  • Bayer (and Merck & Co.)
  • Bristol-Myers Squibb
  • Les Laboratoires Servier
  • Novartis
  • Zensun
  • AstraZeneca
  • Boehringer Ingelheim (and Eli Lilly)
  • Lexicon

第11章 市場未來展望

  • 全球市場
    • 市場預測
    • 急性心臟衰竭 (AHF)
    • 推動及阻礙市場要素:全世界的課題
  • 美國
    • 市場預測
    • 近幾年的主要動向
    • 推動及阻礙市場要素
  • (5EU)歐洲主要5個國家
  • 日本
  • 中國

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC189PIDR

Heart failure( HF) is a clinical syndrome where the heart is unable to meet the demands of the body with a sufficient blood supply. This can be due to structural or functional cardiac abnormalities which can be caused by unexpected injury such as myocardial infarction, or an underlying pathogenesis such as hypertension (Krum and Abraham, 2009). The heart then begins to employ compensatory mechanisms that soon become maladaptive - Frank-Starling mechanism, neurohormonal activation and ventricular remodeling. All of which help to relieve stress initially but long term, cause strain on the cardiac muscle and inevitably progression of HF. Heart failure can be either acute or chronic, depending on the manifestation time frame. Heart failure is grouped into subtypes which are defined by measure of ejection fraction - the heart's ability to eject blood.

HF is a global healthcare concern and affected patients suffer from poor quality of life and poor prognosis. Risk factors for HF include; diabetes, hypertension and obesity, all of which are on the rise in the current population. There is a large unmet need in HF for a treatment option that meets clinical end points in reduced mortality and hospitalization.

Key Highlights

  • The main driver of the HF market expansion will be the approval and launch of the SGLT inhibitors for both HF-REF and HF-PEF.
  • Another prominent contributor to sales growth will be the approval of the large number of pipeline therapies across the 8MM.
  • The major global barrier for the HF market will be the annual cost of therapy for new pipeline drugs compared to the standard of care generics, alongside the unwillingness for prescribers to add new drugs to large therapy regimens.
  • The key market opportunities lie in addressing unmet needs through the development of more efficacious drugs for HF patients for acute HF , HF-PEF and HF-mrEF.

Key Questions Answered

  • SGLT inhibitors will enter the market and see a significant uptake in patient shares for the treatment of HF. However, there are high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfill the unmet needs of the HF market?
  • The current late-stage HF pipeline consists of chronic therapies such as Farxiga and Jardiance, post-acute therapies such as omecamtiv mecarbil and Zynquista, and acute therapies such as istaroxime. Will the late-stage drugs make a significant impact on the HF market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
  • We have seen a significant increase in the HF population, in terms of diagnosed prevalence and there is an increase in the amount of patients treated for HF-REF, HF-PEF and HF-mrEF. How will epidemiological changes impact the growth of the future market?

Scope

  • Overview of HF, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HFtherapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global HF market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global HF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HF therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global HF therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Heart Failure: Executive Summary

  • 2.1 The HF Market Will Exhibit Strong Growth Between 2018 and 2028
  • 2.2 Label Expansions of Anti-Diabetic Drugs Will Fuel Market Growth
  • 2.3 The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline
  • 2.4 Farxiga Will Dominate the Branded HF Market
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
    • 4.1.3 Biomarkers/Targets of Interest
  • 4.2 Classification or Staging Systems
  • 4.3 Prognosis

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF
    • 5.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of HF by EF
    • 5.4.4 Forecast Assumptions and Methods: Acute Hospitalizations
    • 5.4.5 Forecast Assumptions and Methods: Acute Hospitalizations by Worsening CHF, Advanced HF, and De Novo HF
    • 5.4.6 Forecast Assumptions and Methods: Hospital Length of Stay
    • 5.4.7 Forecast Assumptions and Methods: Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
    • 5.4.8 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF
    • 5.4.9 Diagnosed Prevalent Cases of CHF by EF
    • 5.4.10 Diagnosed Prevalent Cases of CHF by NYHA Classes
    • 5.4.11 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CHF by ACCF/AHA Stages
  • 5.5 Epidemiological Forecast for Heart Failure (2018-2028)
    • 5.5.1 Diagnosed Incident Cases of HF
    • 5.5.2 Age-Specific Diagnosed Incident Cases of HF
    • 5.5.3 Sex-Specific Diagnosed Incident Cases of HF
    • 5.5.4 Diagnosed Incident Cases of HF by EF
    • 5.5.5 AHF Hospitalizations
    • 5.5.6 Hospital Length of Stay for AHF Hospitalization
    • 5.5.7 Hospital Readmissions (Within 30 Days) Post-Discharge After AHF Hospitalization
    • 5.5.8 Diagnosed Prevalent Cases of CHF
    • 5.5.9 Diagnosed Prevalent Cases of CHF by EF
    • 5.5.10 Age-Specific Diagnosed Prevalent Cases of CHF
    • 5.5.11 Sex-Specific Diagnosed Prevalent Cases of CHF
    • 5.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class
    • 5.5.13 Diagnosed Prevalent Cases of CHF with PEF by NYHA Class
    • 5.5.14 Diagnosed Prevalent Cases of CHF with REF by NYHA Class
    • 5.5.15 Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

  • 6.1 Diagnosis Overview
  • 6.2 Treatment Overview
    • 6.2.1 Treatment Guidelines and Leading Prescribed Drugs
    • 6.2.2 Clinical Practice
  • 6.3 US
  • 6.4 5EU
  • 6.5 Japan
  • 6.6 China

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: Heart Failure: Key Metrics in the 8MM
  • Table 2: Types of Chronic HF
  • Table 3: Causes of HF
  • Table 4: Compensatory Mechanisms in HF Patients
  • Table 5: Symptoms of Heart Failure
  • Table 6: Key Diagnostic and Prognostic Biomarkers in HF
  • Table 7: A Comparison of Two HF Classification Systems
  • Table 8: Common Factors that Precipitate AHF
  • Table 9: HF Treatment Guidelines Most Commonly Adhered to by Physicians in the 8MM
  • Table 10: Chronic HF-REF Medications Most Commonly Used in the 8MM
  • Table 11: Country Profile - US
  • Table 12: Country Profile - 5EU
  • Table 13: Country Profile - Japan
  • Table 14: Country Profile - China
  • Table 15: Leading Treatments for HF
  • Table 16: Amgen's HF Portfolio Assessment, 2019
  • Table 17: Bayer's HF Portfolio Assessment, 2019
  • Table 18: Bristol-Myers Squibb HF Portfolio Assessment, 2019
  • Table 19: Servier's HF Portfolio Assessment, 2019
  • Table 20: Novartis' Disease Portfolio Assessment, 2019
  • Table 21: Zensun's Disease Portfolio Assessment, 2019
  • Table 22: AstraZeneca's Disease Portfolio Assessment, 2019
  • Table 23: Lexicon's Disease Portfolio Assessment, 2019
  • Table 24: Heart Failure Market - Global Drivers and Barriers, 2018-2028
  • Table 25: Key Events Impacting Sales for HF in the US, 2018-2028
  • Table 26: HF Market - Global Drivers and Barriers in the US, 2018-2028
  • Table 27: Key Events Impacting Sales for Heart Failure in the 5EU, 2018-2028
  • Table 28: Heart Failure Market - Global Drivers and Barriers in the 5EU, 2018-2028
  • Table 29: Key Events Impacting Sales for Heart Failure in Japan, 2018-2028
  • Table 30: Heart Failure Market - Global Drivers and Barriers in Japan, 2018-2028
  • Table 31: Key Events Impacting Sales for Heart Failure in China, 2018-2028
  • Table 32: Heart Failure Market - Global Drivers and Barriers in China, 2018-2028
  • Table 33: Key Historical and Projected Launch Dates for HF
  • Table 34: Key Historical and Projected Patent Expiry Dates for Heart Failure
  • Table 35: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Heart Failure by Country, 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in Heart Failure During the Forecast Period
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2018-2028
  • Figure 4: Changes in Cardiac Structure in HF
  • Figure 5: 8MM, Sources Used to Forecast Hospital Length of Stay for AHF Hospitalization
  • Figure 6: 8MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF
  • Figure 7: 8MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class
  • Figure 8: 8MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, N, 2018
  • Figure 9: 8MM, Sex-Specific Diagnosed Incident Cases of HF, All Ages, N, 2018
  • Figure 10: 8MM, Diagnosed Incident Cases of HF by EF, Both Sexes, All Ages, N, 2018
  • Figure 11: 8MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, All Ages, N, 2018
  • Figure 12: 8MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, All Ages, N, 2018
  • Figure 13: 8MM, Diagnosed Prevalent Cases of CHF by ACCF/AHA Classification, Both Sexes, All Ages, N, 2018
  • Figure 14: Diagnostic Algorithm for Chronic HF
  • Figure 15: Diagnostic Algorithm for Acute HF
  • Figure 16: HF based on the ACCF/AHA staging system
  • Figure 17: Classification of Acute HF Patients
  • Figure 18: Management of Acute HF Patients
  • Figure 19: Unmet Needs and Opportunities in Heart Failure
  • Figure 20: Overview of the Development Pipeline in Heart Failure
  • Figure 21: Competitive Assessment of Late-Stage Pipeline Agents in Chronic and Post-Acute Heart Failure, 2018-2028
  • Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in Acute Heart Failure, 2018-2028
  • Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for HF in the 8MM During the Forecast Period
  • Figure 24: Company Portfolio Gap Analysis in Chronic HF, 2018-2028
  • Figure 25: Company Portfolio Gap Analysis in Acute Heart Failure, 2018-2028
  • Figure 26: Global Sales for Chronic HF by Country, 2018 and 2028
  • Figure 27: Global Sales for Acute HF by Country, 2018 and 2028
  • Figure 28: Sales for Chronic HF by Drug Class in the US, 2018 and 2028
  • Figure 29: Sales for Chronic HF by Drug Class in the 5EU, 2018 and 2028
  • Figure 30: Sales for Chronic HF by Drug Class in Japan, 2018 and 2028
  • Figure 31: Sales for Chronic HF by Drug Class in China, 2018 and 2028